Janssen studies higher initiation dose for paliperidone palmitate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J's Janssen unit is conducting an additional Phase III trial of paliperidone palmitate to further assess a 150 mg equivalent initiation dose of the injectable long-acting form of Invega (paliperidone) for treatment of schizophrenia. The firm announced results of a 13-week study Dec. 10 showing paliperidone palmitate to have a statistically significant symptom control compared to placebo at all doses tested when given every 4 weeks for 13 weeks with a 150 mg eq. initiation dose. Subsequent doses were either 25 mg, 100 mg, or 150 mg eq. An earlier dose-ranging trial using a much lower initiation dose of 50 mg eq. failed to show non-inferiority to risperidone LAT. J&J said Oct. 14 that the drug's launch might have to be pushed back to 2010 to address an FDA "complete response" requesting a re-analysis of a subset of the data (1Pharmaceutical Approvals Monthly September 2008, p. 16)
You may also be interested in...
J&J's Paliperidone Gets "Complete Response" Letter From FDA
No more studies are required, but FDA outlined questions that need to be addressed, according to J&J
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.